Skip to content Accessibility statement

Igor Francetic: CO-PAY OR PROVIDER SWAY? WHAT DRIVES PHYSIOTHERAPY USE IN SWITZERLAND

Seminar

This event has now finished.

Event date
Wednesday 11 November 2026, 1pm to 2pm
Location
In-person only
A/RC014, Alcuin Research Resource Centre, Campus West, University of York (Map)
Audience
Open to staff, students
Admission
Free admission, booking not required

Event details

Author:  Igor Francetic (Manchester)

Abstract: Is patients’ physiotherapy use driven by the cost-sharing they face, or by the providers who treat them? I study this question in the context of the Swiss demand-driven social health insurance system using claims from a large health insurer. Every 1 January the annual deductible resets. A patient who had already exceeded it in 2023 went from paying 10% of each session to paying the full price. The reset effectively bites only for patients on high-deductible plans. Comparing high- and low-deductible patients in treatment over the 2023/24 reset, I find that attendance falls by about 10% and sessions over the following half-year by 13%; the 2022/23 reset shows the same pattern. Patients are forward looking; those who reach the end of a prescribed course of treatment in December are about 10 percentage points less likely to obtain a new prescription, on a base of 36%, before the price has changed. To separate providers from patients’ preferences, I follow patients who switch physiotherapist mid-treatment. Patients pick up the new therapist’s treatment length, so differences in practice style reflect the provider, not the patients it attracts. Moving from the 1st to the 3rd quartile of practice style adds 14% of sessions, about as much as the price shock removes. Prescribing doctors matter less. Neither physiotherapist nor prescriber style changes how patients respond to cost-sharing, even at the renewal that the prescriber signs. Since 2020, physiotherapy spending covered by social health insurance in Switzerland grew by 10% annually. This attracted the interest of policymakers, with views on physiotherapy split between low-value and cost-effective care that prevents more invasive procedures. I find that more intensive physiotherapy is unlikely to reduce drug spending and probability of surgery over a 12-month horizon, providing some initial evidence against the latter hypothesis.

Host(s): Luigi Siciliani/Nigel Rice (York)

Cluster: Health

Contact

Luigi Siciliani/Nigel Rice

luigi.siciliani@york.ac.uk nigel rice@york.ac.uk